From a University spin-out with its first Nature paper to the leading pharmatech innovator at the forefront of AI drug discovery, Exscientia’s journey has been all about breaking new ground to delivering exceptional results.

A snapshot of our key milestones is below.

Our History


Exscientia is founded as a spin-out from the University of Dundee


Sep: Exscientia partners with Sumitomo Dainippon Pharma - Central Nervous System

Nov: Exscientia partners with Sunovion Pharmaceuticals - Psychiatric disorders


Sep: Exscientia delivers first candidate for Sumitomo


Apr: Exscientia partners with Evotec - Immuno-oncology


May: Exscientia signs a strategic research collaboration and licence option agreement with Sanofi - Metabolic diseases

Jul: Exscientia partners with GlaxoSmithKline - Multiple therapeutic areas

Sep: Evotec invests €15 M in Exscientia

Dec: Exscientia opens Oxford office


Nov: Exscientia acquires biophysics specialists Kinetic Discovery

Nov: Exscientia establishes new Headquarters at the Oxford Science Park


Jan: Exscientia raises $26 million in Series B financing round

Jan: Exscientia partners with Roche

Mar: Exscientia expansion with subsidiary in Osaka, Japan

Mar: Exscientia partners with Celgene - Oncology and Autoimmunity

Apr: Exscientia delivers first major milestone in GSK collaboration

Jun: Exscientia partners with GT Apeiron Therapeutics - Oncology

Jul: Exscientia partners with Rallybio - Rare diseases

Aug: Sanofi exercises option to progress an innovative Bispecific small molecule project